Clinical trial
Use of 852A in Metastatic Cutaneous Melanoma.
NCT00189332 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00189332 |
|---|---|
| Title | Use of 852A in Metastatic Cutaneous Melanoma. |
| Official title | Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Unresectable Metatstatic Cutaneous Melanoma |
| Intervention type | Drug |
| Interventions | 852A |
| Enrollment | 28 |
| Start date | Feb 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 27, 2008 |
| Countries | France, Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: